Dr. Vitoc is a well-seasoned biotech executive with a broad array of experience across commercial strategic analysis and planning and medical affairs, in which he has 20 years of experience. He has served on leadership teams in various Oncology companies and business units. He also has a track record of successful organizational capability building, talent recruiting and development, and functional leadership.
His experience includes managing and supporting over 20 early, launch, and mature stage compounds, amongst which targeted therapies and immune therapies, across more than 25 tumor types – amongst which colorectal cancer, hepatocellular carcinoma, lung cancer, breast cancer prostate cancer, renal cell carcinoma. In his previous role at Barricade Therapeutics, he served as the Chief Business Officer and SVP Medical Affairs, leading the capitalization efforts and the pharmaceutical business development activities. At Puma Biotechnology, he served as VP Medical Affairs and built the Medical organization supporting the launch of NERLYNX (neratinib) in extended adjuvant breast cancer. Before Puma, Dr. Vitoc was the Executive Medical Director for pipeline products at Incyte Corporation, establishing the medical affairs support for compounds transitioning from preclinical to phase I and II clinical trials. Before that, he was Sr Medical Director at Astellas Pharma Inc., supporting the launch and development of XTANDI (enzalutamide), the life cycle management of TARCEVA (erlotinib), as well as pipeline compounds. Earlier in his career, he served in commercial strategic analysis and planning leadership roles centered on life cycle management, business development, and forecasting at Cephalon Oncology, Novartis Oncology, Bayer Oncology, and Pharmacia & Upjohn. He obtained his medical training at the University of Medicine and Pharmacy “Iuliu Hatieganu” in Cluj-Napoca, Romania, and his MBA at the University of South Carolina.
Sergei M. Gryaznov, Ph.D., is an internationally recognized scientist and expert in the areas of modern drug discovery and development, oncology, telomerase, immune-regulatory therapeutics, nucleosides, nucleotides, DNA & RNA analogues, lipid and other conjugates, small molecules and nucleic acid based therapeutic agents.
Dr. Gryaznov most recently served as the Head and Scientific Co-founder, Nucleic Acid Center of Excellence, Janssen Pharma, part of Johnson and Johnson family of companies (March 2015 – November 2019). Prior to his work at J&J, Dr. Gryaznov served as the Chief Technology Officer at AuraSense Therapeutics, (now Exicure Inc, XCUR). His work at AuraSense resulted in two APIs, which are currently in two Phase I/II clinical trials, for oncological and inflammatory indications and also enabled the company’s IPO, (February 2013-March 2015). Dr. Gryaznov also worked as the Director of Chemistry & Sr. Research Fellow with Geron Corporation, from 1998 until January 2013, where he defined major scientific and drug-discovery directions for the company. While at Geron, he has created unique and powerful broad-spectrum therapeutic and diagnostic/imaging technology platforms. One of the main results of his work was first-in-class, first-in-clinic telomerase inhibitor Imetelstat Sodium (GRN163L), which is currently in Phase III trials in hematological cancers. Dr. Gryaznov was also the co-inventor of a novel telomere-by-telomerase-targeting therapeutic approach to potential cancer treatment. Prior to joining Geron Corp., Dr. Gryaznov was at Lynx Therapeutics Inc. (now part of Illumina Inc.), as a scientific co-founder, from 1993 until 1997. At Lynx Therapeutics, Dr. Gryaznov discovered novel DNA and RNA analogues, suitable for variety oligonucleotide-derived applications.
Dr. Gryaznov’s research interests also extend into the fields of origin of life and modern DNA and RNA, RNA splicing, non-enzymatic nucleic acids replication, oligonucleotide chemical auto-ligation, lipid and peptide conjugates, nucleosides/nucleotides chemistry, and lipids in vitro/in vivo regulation. Dr. Gryaznov completed his post-doctoral training with Prof. Robert L. Letsinger at Northwestern University. He received his Ph.D degree in nucleic acid and natural products biochemistry from M.V. Lomonosov Moscow University (under Prof. Zoe Shabarova), and then worked as a Research Scientist with Prof. Eugene Sverdlov at M.M. Shemyakin Institute of Bioorganic Chemistry in Moscow, Russia. Dr. Gryaznov has co-authored more than 120 peer-reviewed scientific publications, and he is a co-inventor of more than 50 issued and pending U.S and international patents. He has established numerous successful collaboration projects with various academic laboratories and institutions world-wide.
Mihail is a hematologist/oncologist with over 20 years’ experience in drug development in both academia and pharmaceutical/biotechnology industry with expertise in the development of cell therapy, cancer vaccines, monoclonal antibodies, and small molecules. Mihail has played an instrumental role in the development and commercialization of numerous drugs including IMBRUVICA,® Besponsa,® and BREYANZI.® Prior to joining MAIA, he served as Project and Clinical Lead at Atara Biotherapeutics where he supported the clinical development of the Atara’s allogeneic CAR T platform. Prior to that, he held multiple senior level positions over the last two decades including leading the Medical Affairs Oncology group at MedImmune, serving as VP, Clinical Development Oncology at MannKind Corp., Global Project Lead for AbbVie Biotherapeutics, Head, Medical Sciences at Pharmacyclics, VP of Clinical and Medical Affairs at SFJ Pharmaceutical Group, US Clinical Lead at Nanobiotix Corp, and clinical Program Lead at Juno Therapeutics Inc. Mihail’s research has been published in oncology peer-reviewed literature, he has co-authored published books related to cancer vaccines and immunology, and he holds several patents in the field of biotechnology.
Mihail received his M.D. from the Faculty of Medicine and Pharmacy, Bucharest, Romania and completed an internship and residency program in Internal Medicine at Yale-New Haven affiliated hospitals in Connecticut followed by a fellowship program in hematology/oncology and later appointed as Instructor of Medicine, division of Hematology & Oncology at Mary Hitchcock Medical Center and Geisel Medical School at Dartmouth in New Hampshire.
Dan Relovsky is the Chief Operating Officer for Maia Biotechnology, Inc. He is a general management, operations and commercialization specialist that has served in the pharmaceutical and biotechnology industries for over 25 years.
Mr. Relovsky was the founding and managing partner for Clarity Global Solutions LLC, a consulting firm specializing in commercial value development and operational support to biotech and pharmaceutical companies, with primary focus on early-mid stage asset development and product planning building commercial value. Additionally, CGS specializes in therapeutic area market development and engagement, Medical Affairs and Commercial Operations management, with particular focus on commercialization and launch preparation.
Mr. Relovsky began his career in Finance for Squibb-Novo, Inc. (now Novo Nordisk Pharmaceuticals, Inc.) and over the years has held various management positions, with increasing levels of responsibility, including leading operations functional areas, Product Planning and Marketing, addressing both company-wide and product level initiatives. Most recently, Mr. Relovsky has established and led the Commercial Operations and launch planning for ARS Pharmaceuticals, Inc. for an intranasal form of epinephrine (ARS-1). Prior to ARS, he led Medical Affairs Operations for Puma Biotechnology, Inc. through the launch of NERLYNX (neratinib), a tyrosine kinase inhibitor approved for the treatment of breast cancer. He has also held positions leading Commercial Operations for Somaxon Pharmaceuticals, Inc. which launched SILENOR (doxepin) for the treatment of insomnia; and Marketing for Cephalon, Inc. where he established the oncology franchise that included the product re-launch of TRISENOX (arsenic trioxide) in acute promyelocytic leukemia (APL) and launch of TREANDA (bendamustine) in two indications: chronic lymphocytic leukemia (CLL) and indolent non-hodgkin lymphoma (NHL). Other previous positions include product planning and marketing with Salmedix, Inc., Maxim Pharmaceuticals, Inc.; and commercial operations with Agouron Pharmaceutics, Inc. all based in San Diego, CA; and IMS Health (now IQVIA). Additionally, Mr. Relovsky held the role of Vice President, Development & Board Member for the American Melanoma Foundation.
Mr. Relovsky holds a Bachelor of Science, Business Administration and Finance from Drexel University in Philadelphia, PA.